Article
Patient Decisions to Receive Secondary Pharmacogenomic Findings and Development of a Multidisciplinary Practice Model to Integrate Results Into Patient Care.
Clinical and translational science - 1 Jan 2018
Hicks J Kevin, Shealy Amy, Schreiber Allison, Coleridge Marissa, Noss Ryan, Natowicz Marvin, Moran Rocio, Moss Timothy, Erwin Angelika, Eng Charis
Abstract excerpt
Whole exome sequencing (WES) has the potential of identifying secondary findings that are predictive of poor pharmacotherapy outcomes. The purpose of this study was to investigate patients' wishes regarding the reporting of secondary pharmacogenomic findings. WES results (n = 106 patients) were retrospectively reviewed to determine the number of patients electing to receive secondary pharmacogenomic results....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.